ID   L1210:RD1694
AC   CVCL_Y424
SY   L1210 (RD1694); L1210(RD1694)
DR   ChEMBL-Cells; CHEMBL3307418
DR   ChEMBL-Targets; CHEMBL614713
DR   PubChem_Cell_line; CVCL_Y424
DR   Wikidata; Q54900970
RX   PubMed=7537518;
CC   Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; ZD1694).
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0382 ! L1210
SX   Female
AG   8M
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 05-10-23; Version: 13
//
RX   PubMed=7537518; DOI=10.1038/bjc.1995.178;
RA   Jackman A.L., Kelland L.R., Kimbell R., Brown M., Gibson W.,
RA   Aherne G.W., Hardcastle A., Boyle F.T.;
RT   "Mechanisms of acquired resistance to the quinazoline thymidylate
RT   synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell
RT   lines.";
RL   Br. J. Cancer 71:914-924(1995).
//